We strive to address one of the world’s most complex problems: drug discovery.
New drug development cost: $2.6 billion. Success rate: below 10%.
One of the first phases of drug discovery for a chosen target concerns high-throughput screening. Machine learning has the potential to substantially accelerate the drug discovery lifecycle by performing virtual screening of large databases of candidate drug molecules against a specific target a protein associated with some known disease. At the same time current approaches for structure-based virtual screening are slow.
Our unique proposition is a Virtual Screening as a Service (VSaaS) solution.
We propose a service for fast virtual screening, suitable for massive databases with minimal requirements.
DeNViS can be employed for tasks within early-stage drug discovery: drug repurposing, repositioning and potentially other applications within the drug discovery pipeline.
104x speed-up compared to state-of-the-art docking-based approaches such as gina, vina etc. DeNViS can be employed to screen billions of compounds in a matter of hours.
State-of-the-art performance employing algorithms in geometric deep learning, outperforming docking-based approaches in binding affinity prediction tasks evaluated in multiple benchmarks.
What our collaborators say about DeNViS
"Leveraging its extensive deep learning expertise, DeepLab's virtual screening approach is a novel, high throughput methodology in binding affinity elucidation. Fueled by state-of-the-art machine learning methods, this approach is propelling drug-repurposing into an exciting future."
Postdoctoral Researcher in Cardiac Transcriptomics & Data Analysis
"DeepLab enables you to reimagine how healthcare is delivered. By using state of the art scientific approaches to drug discovery, we apply ideas that are novel and life-changing!"
HealthTech Business & Market Analysis Consultant